| |
Redefine what it means to be inspection-ready with Premier’s Inspection Readiness Program. This four-phase plan will arm you with the knowledge, skills, and confidence to successfully host health authority inspections. Get started with our brochure. 
|
|
Today’s Big NewsOct 22, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. .png)
|
|
| By James Waldron Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact at the same time as it searches for a partner for its more advanced ex vivo sickle cell disease (SCD) medicine. |
|
|
|
By Nick Paul Taylor Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data. |
By James Waldron AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof that it can generate CAR-T cells that can be turned “on” once inside a patient. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
|
- 45 markers for cytokine signaling/inflammation
- Trust RBM for Olink, Luminex & Simoa immunoassays
|
|
By James Waldron Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by being shown in an interim analysis to have reduced patients’ urine protein-to-creatine ratio levels. |
Sponsored by TriNetX, Inc. Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and site selection. |
By Gabrielle Masson China-based Minghui Pharmaceutical has linked its thyroid eye disease treatment to a reduction in eye bulging in a small phase 1b/2 clinical trial. |
By Darren Incorvaia Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate. The small molecule RTY-694 is meant to treat the rare liver disease primary sclerosing cholangitis by restoring and enhancing the function of two cell membrane proteins in the ABC transporter family. |
By Angus Liu Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation. |
By Kevin Dunleavy Two years after emerging with its initial funding round, CDMO Nucleus RadioPharma is going bicoastal, revealing expansions at two sites that the company believes will "significantly improve” market access to the promising cancer treatments. |
By Andrea Park The upcoming winter months bring with them the annual cold and flu season, as well as “cuffing season” for singles everywhere, and consumer health giant Reckitt is capitalizing on both occurrences. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
